Symbols / CYDY $0.34 -5.75% CytoDyn Inc.
CYDY Chart
About
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Fundamentals
Scroll to Statements| Market Cap | 463.49M | Enterprise Value | 478.84M | Income | -40.28M | Sales | — | Book/sh | -0.08 | Cash/sh | 0.01 |
| Dividend Yield | — | Payout | 0.00% | Employees | 13 | IPO | — | P/E | — | Forward P/E | -1.89 |
| PEG | — | P/S | — | P/B | -4.41 | P/C | — | EV/EBITDA | -22.38 | EV/Sales | — |
| Quick Ratio | 0.31 | Current Ratio | 0.37 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -0.04 | EPS next Y | -0.18 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-04-08 | ROA | -67.45% | ROE | — | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.37B | Shs Float | 1.37B | Short Float | — |
| Short Ratio | — | Short Interest | — | 52W High | 0.45 | 52W Low | 0.21 | Beta | 1.17 | Avg Volume | 1.84M |
| Volume | 4.56M | Target Price | — | Recom | None | Prev Close | $0.36 | Price | $0.34 | Change | -5.75% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2020-07-06 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2020-04-28 | reit | HC Wainwright & Co. | — → Buy | $4 |
| 2020-04-03 | reit | HC Wainwright & Co. | — → Buy | $3 |
| 2019-12-19 | reit | HC Wainwright & Co. | — → Buy | $2 |
| 2019-09-16 | reit | HC Wainwright & Co. | — → Buy | $1 |
- CytoDyn (CYDY) files S-1 to register 278M shares for selling stockholders - Stock Titan Wed, 22 Apr 2026 21
- CYDY Stock Falls Despite Positive Cancer Study Data – Retail Says CytoDyn Is ‘Here To Stay’ - Stocktwits Wed, 22 Apr 2026 15
- For hard-to-treat colorectal cancer, CytoDyn combo shows 70% tumor DNA drop - Stock Titan Wed, 22 Apr 2026 12
- CytoDyn Secures $30 Million Commitment from Yorkville Advisors - CytoDyn Inc. Mon, 03 Nov 2025 08
- CytoDyn fills 60-patient colorectal cancer trial across 7 U.S. sites - Stock Titan ue, 21 Apr 2026 20
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab - CytoDyn Inc. hu, 05 Mar 2026 08
- Breast cancer study ties CytoDyn drug to 5-year survival in some patients - Stock Titan Mon, 20 Apr 2026 12
- $17.5M bet on cancer drug leronlimab for tough breast, colon tumors - Stock Titan hu, 05 Mar 2026 08
- 5 metastatic breast cancer patients alive 63 months after leronlimab - Stock Titan Fri, 20 Feb 2026 08
- Two leronlimab cancer studies put CytoDyn on the AACR 2026 agenda - Stock Titan ue, 14 Apr 2026 12
- CYDY SEC Filings - Cytodyn Inc 10-K, 10-Q, 8-K Forms - Stock Titan hu, 02 Apr 2026 07
- CytoDyn (CYDY) sets 2026 CRC, mTNBC Phase 2 plans after leronlimab survival data - Stock Titan ue, 16 Dec 2025 08
- CytoDyn (OTCQB: CYDY) obtains $30M Yorkville equity facility over 36 months - Stock Titan Mon, 03 Nov 2025 08
- CytoDyn (OTCQB: CYDY) inks class action resolution deal, pending court approval - Stock Titan Mon, 01 Dec 2025 08
- 375.9M shares prospectus; CYDY extends notes, agrees monthly share payments (CYDY) - Stock Titan Wed, 25 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.27
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.27
|
| Cost Of Revenue |
|
—
|
0.00
-100.00%
|
20.63
+38830.19%
|
0.05
|
| Reconciled Cost Of Revenue |
|
—
|
0.00
-100.00%
|
20.63
+38830.19%
|
0.05
|
| Gross Profit |
|
—
|
0.00
+100.00%
|
-20.63
-9786.85%
|
0.21
|
| Operating Expense |
|
-9.66
-153.50%
|
18.06
-9.45%
|
19.94
-86.30%
|
145.62
|
| Research And Development |
|
-16.92
-333.72%
|
7.24
+175.08%
|
2.63
-90.27%
|
27.04
|
| Selling General And Administration |
|
7.26
-32.89%
|
10.82
-36.87%
|
17.14
-61.32%
|
44.30
|
| General And Administrative Expense |
|
7.26
-32.89%
|
10.82
-36.87%
|
17.14
-61.32%
|
44.30
|
| Salaries And Wages |
|
2.38
-51.65%
|
4.92
-40.95%
|
8.34
-33.84%
|
12.60
|
| Other Gand A |
|
3.64
-10.01%
|
4.05
-36.79%
|
6.40
-76.46%
|
27.19
|
| Other Operating Expenses |
|
—
|
—
|
20.63
-71.92%
|
73.49
|
| Total Expenses |
|
-9.66
-153.50%
|
18.06
-55.50%
|
40.58
-72.15%
|
145.67
|
| Operating Income |
|
9.66
+153.50%
|
-18.06
+55.50%
|
-40.58
+72.09%
|
-145.40
|
| Total Operating Income As Reported |
|
-9.66
+46.50%
|
-18.06
+55.50%
|
-40.58
+72.09%
|
-145.40
|
| EBITDA |
|
8.59
+119.50%
|
-44.08
+39.54%
|
-72.90
+62.61%
|
-194.97
|
| Normalized EBITDA |
|
9.04
+129.67%
|
-30.47
+52.51%
|
-64.15
+66.44%
|
-191.12
|
| Reconciled Depreciation |
|
0.02
-37.93%
|
0.03
-83.43%
|
0.17
-77.59%
|
0.78
|
| EBIT |
|
8.58
+119.44%
|
-44.11
+39.64%
|
-73.07
+62.67%
|
-195.75
|
| Total Unusual Items |
|
-0.45
+96.73%
|
-13.61
-55.54%
|
-8.75
-127.10%
|
-3.85
|
| Total Unusual Items Excluding Goodwill |
|
-0.45
+96.73%
|
-13.61
-55.54%
|
-8.75
-127.10%
|
-3.85
|
| Special Income Charges |
|
0.41
+103.04%
|
-13.37
|
0.00
+100.00%
|
-3.85
|
| Other Special Charges |
|
—
|
13.37
|
—
|
3.85
|
| Impairment Of Capital Assets |
|
—
|
—
|
—
|
0.00
|
| Restructuring And Mergern Acquisition |
|
-0.41
|
0.00
|
—
|
—
|
| Write Off |
|
—
|
—
|
—
|
73.49
|
| Net Income |
|
3.75
+107.51%
|
-49.84
+37.56%
|
-79.82
+62.14%
|
-210.82
|
| Pretax Income |
|
3.75
+107.51%
|
-49.84
+37.56%
|
-79.82
+62.14%
|
-210.82
|
| Net Non Operating Interest Income Expense |
|
-5.47
+69.89%
|
-18.17
+40.41%
|
-30.50
+50.46%
|
-61.56
|
| Interest Expense Non Operating |
|
4.83
-15.76%
|
5.74
-15.04%
|
6.75
-55.20%
|
15.07
|
| Net Interest Income |
|
-5.47
+69.89%
|
-18.17
+40.41%
|
-30.50
+50.46%
|
-61.56
|
| Interest Expense |
|
4.83
-15.76%
|
5.74
-15.04%
|
6.75
-55.20%
|
15.07
|
| Interest Income Non Operating |
|
0.56
+160.37%
|
0.22
|
—
|
—
|
| Interest Income |
|
0.56
+160.37%
|
0.22
|
—
|
—
|
| Other Income Expense |
|
-0.45
+96.73%
|
-13.61
-55.54%
|
-8.75
-127.10%
|
-3.85
|
| Gain On Sale Of Security |
|
-0.85
-261.02%
|
-0.24
+97.30%
|
-8.75
|
—
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
3.75
+107.51%
|
-49.84
+37.56%
|
-79.82
+62.14%
|
-210.82
|
| Net Income From Continuing Operation Net Minority Interest |
|
3.75
+107.51%
|
-49.84
+37.56%
|
-79.82
+62.14%
|
-210.82
|
| Net Income From Continuing And Discontinued Operation |
|
3.75
+107.51%
|
-49.84
+37.56%
|
-79.82
+62.14%
|
-210.82
|
| Net Income Continuous Operations |
|
3.75
+107.51%
|
-49.84
+37.56%
|
-79.82
+62.14%
|
-210.82
|
| Normalized Income |
|
4.19
+111.56%
|
-36.23
+49.02%
|
-71.07
+65.66%
|
-206.97
|
| Net Income Common Stockholders |
|
—
|
—
|
—
|
—
|
| Otherunder Preferred Stock Dividend |
|
—
|
0.00
-100.00%
|
5.42
|
0.00
|
| Diluted EPS |
|
0.00
+100.00%
|
-0.05
+50.00%
|
-0.10
+67.74%
|
-0.31
|
| Basic EPS |
|
0.00
+100.00%
|
-0.05
+50.00%
|
-0.10
+67.74%
|
-0.31
|
| Basic Average Shares |
|
1,205.76
+24.37%
|
969.51
+15.90%
|
836.53
+23.58%
|
676.90
|
| Diluted Average Shares |
|
1,242.92
+28.20%
|
969.51
+15.90%
|
836.53
+23.58%
|
676.90
|
| Diluted NI Availto Com Stockholders |
|
2.26
+104.41%
|
-51.32
+40.83%
|
-86.74
+59.17%
|
-212.45
|
| Amortization |
|
—
|
0.00
-100.00%
|
0.13
|
—
|
| Amortization Of Intangibles Income Statement |
|
—
|
0.00
-100.00%
|
0.13
|
—
|
| Depreciation Amortization Depletion Income Statement |
|
—
|
0.03
-83.43%
|
0.17
-77.59%
|
0.78
|
| Depreciation And Amortization In Income Statement |
|
—
|
0.03
-83.43%
|
0.17
-77.59%
|
0.78
|
| Depreciation Income Statement |
|
—
|
0.03
-32.56%
|
0.04
|
—
|
| Insurance And Claims |
|
1.24
-33.03%
|
1.85
-22.88%
|
2.40
-46.83%
|
4.51
|
| Preferred Stock Dividends |
|
1.48
+0.00%
|
1.48
-0.80%
|
1.50
-8.17%
|
1.63
|
| Total Other Finance Cost |
|
1.21
-90.48%
|
12.65
-46.71%
|
23.75
-48.93%
|
46.50
|
| Line Item | Trend | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|---|
| Total Assets |
|
18.05
+62.06%
|
11.14
-1.38%
|
11.29
-61.31%
|
29.18
|
| Current Assets |
|
17.88
+65.31%
|
10.81
+0.09%
|
10.80
+2.76%
|
10.52
|
| Cash Cash Equivalents And Short Term Investments |
|
11.90
+282.73%
|
3.11
+22.39%
|
2.54
-39.94%
|
4.23
|
| Cash And Cash Equivalents |
|
11.90
+282.73%
|
3.11
+22.39%
|
2.54
-39.94%
|
4.23
|
| Cash Financial |
|
11.90
+282.73%
|
3.11
+22.39%
|
2.54
-39.94%
|
4.23
|
| Receivables |
|
2.00
|
0.00
|
—
|
—
|
| Other Receivables |
|
2.00
|
—
|
—
|
—
|
| Inventory |
|
—
|
—
|
—
|
17.93
|
| Raw Materials |
|
—
|
—
|
—
|
16.26
|
| Work In Process |
|
—
|
—
|
—
|
1.67
|
| Prepaid Assets |
|
3.98
+297.10%
|
1.00
-43.03%
|
1.76
-72.04%
|
6.28
|
| Restricted Cash |
|
0.00
-100.00%
|
6.70
+3.03%
|
6.51
|
0.00
|
| Total Non Current Assets |
|
0.17
-47.35%
|
0.32
-34.09%
|
0.49
-97.41%
|
18.80
|
| Net PPE |
|
—
|
—
|
—
|
0.61
|
| Gross PPE |
|
—
|
—
|
—
|
0.61
|
| Other Properties |
|
—
|
—
|
—
|
0.61
|
| Goodwill And Other Intangible Assets |
|
—
|
—
|
0.00
-100.00%
|
0.13
|
| Other Intangible Assets |
|
—
|
—
|
—
|
0.13
|
| Other Non Current Assets |
|
0.17
-47.35%
|
0.32
-34.09%
|
0.49
-97.39%
|
18.67
|
| Total Liabilities Net Minority Interest |
|
114.09
-10.79%
|
127.89
+5.88%
|
120.79
-2.26%
|
123.58
|
| Current Liabilities |
|
70.52
-16.23%
|
84.18
-29.73%
|
119.80
-2.73%
|
123.16
|
| Payables And Accrued Expenses |
|
42.75
-20.85%
|
54.01
-36.32%
|
84.83
-0.44%
|
85.20
|
| Payables |
|
22.96
-36.84%
|
36.35
-46.57%
|
68.03
-5.45%
|
71.95
|
| Accounts Payable |
|
14.69
-50.30%
|
29.56
-52.87%
|
62.73
-7.72%
|
67.97
|
| Other Payable |
|
—
|
—
|
0.14
+3.73%
|
0.13
|
| Dividends Payable |
|
8.27
+21.76%
|
6.79
+27.94%
|
5.31
+33.47%
|
3.98
|
| Current Accrued Expenses |
|
19.79
+12.07%
|
17.66
+5.17%
|
16.79
+26.75%
|
13.25
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.28
+33.65%
|
0.21
-37.91%
|
0.34
-77.99%
|
1.52
|
| Current Debt And Capital Lease Obligation |
|
27.34
-8.67%
|
29.93
-13.37%
|
34.56
-5.00%
|
36.38
|
| Current Debt |
|
27.20
-8.70%
|
29.79
-13.44%
|
34.42
-5.03%
|
36.24
|
| Other Current Borrowings |
|
27.20
-8.70%
|
29.79
-13.44%
|
34.42
-5.03%
|
36.24
|
| Current Capital Lease Obligation |
|
0.14
-0.70%
|
0.14
+2.16%
|
0.14
+3.73%
|
0.13
|
| Other Current Liabilities |
|
0.14
+480.00%
|
0.03
-68.35%
|
0.08
+23.44%
|
0.06
|
| Total Non Current Liabilities Net Minority Interest |
|
43.57
-0.32%
|
43.71
+4284.35%
|
1.00
+136.26%
|
0.42
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
-100.00%
|
0.14
-85.86%
|
1.00
+136.26%
|
0.42
|
| Long Term Debt |
|
—
|
—
|
0.71
|
—
|
| Long Term Capital Lease Obligation |
|
0.00
-100.00%
|
0.14
-50.18%
|
0.28
-32.94%
|
0.42
|
| Other Non Current Liabilities |
|
43.57
+0.00%
|
43.57
|
—
|
—
|
| Stockholders Equity |
|
-96.04
+17.74%
|
-116.76
-6.63%
|
-109.50
-16.00%
|
-94.40
|
| Common Stock Equity |
|
-96.04
+17.74%
|
-116.76
-6.63%
|
-109.50
-16.00%
|
-94.40
|
| Capital Stock |
|
1.25
+17.94%
|
1.06
+15.23%
|
0.92
+27.64%
|
0.72
|
| Common Stock |
|
1.25
+17.94%
|
1.06
+15.23%
|
0.92
+27.64%
|
0.72
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
1,249.46
+17.98%
|
1,059.00
+15.23%
|
919.05
+27.64%
|
720.03
|
| Ordinary Shares Number |
|
1,249.17
+18.01%
|
1,058.56
+15.23%
|
918.61
+27.66%
|
719.59
|
| Treasury Shares Number |
|
0.29
-35.44%
|
0.44
+0.00%
|
0.44
+0.00%
|
0.44
|
| Additional Paid In Capital |
|
790.50
+2.17%
|
773.71
+5.80%
|
731.27
+8.98%
|
671.01
|
| Retained Earnings |
|
-887.79
+0.42%
|
-891.53
-5.92%
|
-841.69
-9.86%
|
-766.13
|
| Treasury Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Total Equity Gross Minority Interest |
|
-96.04
+17.74%
|
-116.76
-6.63%
|
-109.50
-16.00%
|
-94.40
|
| Total Capitalization |
|
-96.04
+17.74%
|
-116.76
-7.33%
|
-108.79
-15.24%
|
-94.40
|
| Working Capital |
|
-52.64
+28.25%
|
-73.37
+32.69%
|
-108.99
+3.24%
|
-112.65
|
| Invested Capital |
|
-68.84
+20.84%
|
-86.97
-16.94%
|
-74.37
-27.88%
|
-58.16
|
| Total Debt |
|
27.34
-9.09%
|
30.08
-15.41%
|
35.55
-3.38%
|
36.80
|
| Net Debt |
|
15.30
-42.67%
|
26.68
-18.13%
|
32.59
+1.81%
|
32.01
|
| Capital Lease Obligations |
|
0.14
-50.18%
|
0.28
-32.94%
|
0.42
-24.10%
|
0.56
|
| Net Tangible Assets |
|
-96.04
+17.74%
|
-116.76
-6.63%
|
-109.50
-15.84%
|
-94.53
|
| Tangible Book Value |
|
-96.04
+17.74%
|
-116.76
-6.63%
|
-109.50
-15.84%
|
-94.53
|
| Interest Payable |
|
18.15
+19.20%
|
15.23
+43.68%
|
10.60
+77.40%
|
5.97
|
| Line Item | Trend | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-8.77
+20.19%
|
-10.98
+56.26%
|
-25.11
+67.69%
|
-77.72
|
| Cash Flow From Continuing Operating Activities |
|
-8.77
+20.19%
|
-10.98
+56.26%
|
-25.11
+67.69%
|
-77.72
|
| Net Income From Continuing Operations |
|
3.75
+107.51%
|
-49.84
+37.56%
|
-79.82
+62.14%
|
-210.82
|
| Depreciation Amortization Depletion |
|
0.02
-37.93%
|
0.03
-83.43%
|
0.17
-77.59%
|
0.78
|
| Depreciation |
|
0.02
-37.93%
|
0.03
-32.56%
|
0.04
|
—
|
| Amortization Cash Flow |
|
—
|
0.00
-100.00%
|
0.13
|
—
|
| Depreciation And Amortization |
|
0.02
-37.93%
|
0.03
-83.43%
|
0.17
-77.59%
|
0.78
|
| Amortization Of Intangibles |
|
—
|
0.00
-100.00%
|
0.13
|
—
|
| Other Non Cash Items |
|
—
|
4.47
-88.05%
|
37.39
+87.10%
|
19.98
|
| Stock Based Compensation |
|
1.61
-33.25%
|
2.42
-43.51%
|
4.28
-31.48%
|
6.24
|
| Asset Impairment Charge |
|
—
|
—
|
20.63
-71.92%
|
73.49
|
| Deferred Tax |
|
—
|
—
|
—
|
—
|
| Deferred Income Tax |
|
—
|
—
|
—
|
—
|
| Operating Gains Losses |
|
2.03
-89.99%
|
20.29
+44.23%
|
14.07
-62.37%
|
37.38
|
| Gain Loss On Investment Securities |
|
0.85
+261.02%
|
0.24
-97.30%
|
8.76
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
1.18
-82.34%
|
6.68
+25.75%
|
5.31
-85.79%
|
37.38
|
| Change In Working Capital |
|
-16.17
-238.72%
|
11.66
+1075.56%
|
-1.20
+74.99%
|
-4.78
|
| Change In Receivables |
|
—
|
—
|
—
|
0.00
|
| Change In Inventory |
|
—
|
—
|
0.00
-100.00%
|
2.06
|
| Change In Prepaid Assets |
|
-4.84
-641.99%
|
0.89
-53.05%
|
1.90
+146.11%
|
-4.12
|
| Change In Payables And Accrued Expense |
|
-11.33
-205.27%
|
10.77
+447.59%
|
-3.10
-14.15%
|
-2.71
|
| Investing Cash Flow |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
—
|
—
|
—
|
0.00
|
| Net PPE Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of PPE |
|
—
|
—
|
—
|
0.00
|
| Capital Expenditure |
|
—
|
—
|
—
|
—
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
—
|
—
|
| Purchase Of Intangibles |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
10.85
-7.61%
|
11.75
-60.74%
|
29.93
-37.67%
|
48.01
|
| Cash Flow From Continuing Financing Activities |
|
10.85
-7.61%
|
11.75
-60.74%
|
29.93
-37.67%
|
48.01
|
| Net Issuance Payments Of Debt |
|
-0.71
-135.31%
|
2.01
+124.69%
|
0.90
|
0.00
|
| Issuance Of Debt |
|
0.00
-100.00%
|
2.01
+124.69%
|
0.90
|
0.00
|
| Repayment Of Debt |
|
-0.71
|
0.00
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Short Term Debt Issuance |
|
0.00
-100.00%
|
2.01
+124.69%
|
0.90
|
—
|
| Short Term Debt Payments |
|
-0.71
|
0.00
|
—
|
—
|
| Net Short Term Debt Issuance |
|
-0.71
-135.31%
|
2.01
+124.69%
|
0.90
|
—
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
9.14
-64.57%
|
25.79
-37.41%
|
41.20
|
| Cash Dividends Paid |
|
—
|
—
|
—
|
0.00
|
| Proceeds From Stock Option Exercised |
|
11.56
+3754.67%
|
0.30
-90.76%
|
3.25
-52.38%
|
6.82
|
| Net Other Financing Charges |
|
—
|
0.30
|
—
|
—
|
| Changes In Cash |
|
2.09
+172.72%
|
0.77
-84.10%
|
4.82
+116.21%
|
-29.71
|
| Beginning Cash Position |
|
9.81
+8.47%
|
9.05
+113.85%
|
4.23
-87.53%
|
33.94
|
| End Cash Position |
|
11.90
+21.29%
|
9.81
+8.47%
|
9.05
+113.85%
|
4.23
|
| Free Cash Flow |
|
-8.77
+20.19%
|
-10.98
+56.26%
|
-25.11
+67.69%
|
-77.72
|
| Interest Paid Supplemental Data |
|
0.03
-44.44%
|
0.04
+136.84%
|
0.02
-69.84%
|
0.06
|
| Common Stock Issuance |
|
0.00
-100.00%
|
9.14
-64.57%
|
25.79
-37.41%
|
41.20
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
9.14
-64.57%
|
25.79
-37.41%
|
41.20
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Dividend Paid |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-04-08 View
- 42026-03-24 View
- 42026-03-24 View
- 42026-03-24 View
- 42026-03-24 View
- 42026-03-24 View
- 42026-03-24 View
- 42026-03-24 View
- 42026-03-24 View
- 8-K2026-03-24 View
- 8-K2026-03-05 View
- 10-Q2026-01-09 View
- 8-K2025-12-01 View
- 8-K2025-11-21 View
- 8-K2025-11-03 View
- 10-Q2025-10-10 View
- 10-K2025-07-25 View
- 42025-05-22 View
- 8-K2025-05-16 View
- 8-K2025-05-06 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|